Key facts
- Curadel Pharma’s last known valuation is $107.5M (Oct 2025).
- It has raised $26.0M; the latest was Later Stage VC ($14.5M) in Oct 2025.
- Notable investors include National Cancer Institute, National Institute of Biomedical Imaging and Bioengineering, National Institute of Dental and Craniofacial Research.
- Status: Privately Held (backing).
- ·The complete investor list — 3 names
- ·Watchlist + deal alerts for Curadel Pharma
- ·The full record, as it builds
Funding rounds
No funding rounds for Curadel Pharma are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Curadel Pharma
Developer of optical imaging systems designed to see the invisible and minute internal body parts. The company uses fluorescent near-infrared light, a special camera system, and an illumination technique to make imaging suitable for open operation and even minimally invasive surgery, enabling surgeons to see and operate cells and tissues in detail to avoid accidents during critical cancer surgeries.
- Sector
- Healthcare
- HQ
- Natick, MA, United States
- Founded
- 2012
- Employees
- 24
- Website
- curadelpharma.com/
- Ownership
- Privately Held (backing)
Curadel Pharma doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Curadel Pharma shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Curadel Pharma in its N-PORT filings yet. We sweep new filings monthly.